CDT Equity Files Sarborg Financials: $30.9M Warrant Dilution and Sarborg's Own Going Concern Warning
CDT is trading near its 52-week low of $2.53 (15% above the low).
Summary
CDT Equity's 8-K/A reveals Sarborg's audited financials show a going concern warning and minimal cash, while the pro forma statements quantify the warrant dilution at $30.9 million.
Key Events · M&A and Partnerships · CDT
-
Sarborg Financials Reveal Going Concern
Sarborg's audited financials show an accumulated deficit of $0.8M, cash of only $10K as of Dec 31, 2025, and a going concern warning. Interim H1 2026 statements show cash of $14K and a net loss of $485K.
-
Warrant Dilution Quantified at $30.9M
The pro forma balance sheet records $30.9 million in additional paid-in capital from the issuance of pre-funded warrants to purchase up to 12,131,770 shares of CDT common stock, valued at the July 30, 2026 closing price.
-
Sarborg's $65M Intangible Asset
Sarborg's H1 2026 balance sheet includes a $65 million intangible asset from the April 13, 2026 Patent Assignment Agreement with Manoira Corporation, paid for with new ordinary shares representing 10% of Sarborg's fully diluted capital.
-
CDT's Equity Method Investment
CDT now owns 24.76% of Sarborg (1,290 shares) and accounts for it under the equity method. The pro forma statements show a $23K loss on the additional investment for H1 2026 and a $126K loss for FY2025.
Analysis · CDT · Life Sciences
This amendment provides the first look at Sarborg's audited financials, which reveal Sarborg itself has a going concern warning and only $14K in cash as of June 30, 2026. The pro forma statements quantify the dilution from the pre-funded warrants at $30.9 million, and the filing confirms CDT will issue up to 12.1 million warrants for a 4.76% stake in Sarborg. For a company with a market cap near $2 million, this is a highly dilutive transaction that also exposes CDT to a financially distressed investee.
How filings like this one have moved
In the 30 days to Oct 19, 2026, 37.9% of the 895 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.87%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CDT was trading at $2.90 on NASDAQ in the Life Sciences sector. The 52-week trading range was $2.53 to $3,460.60. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.